Company Description
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy.
Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.
The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation.
It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally.
The company was incorporated in 2003 and is headquartered in Elmsford, New York.
| Country | United States |
| Founded | 2003 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Brian M. Murphy |
Contact Details
Address: 525 Executive Blvd Elmsford, New York 10523 United States | |
| Phone | (914) 233-3004 |
| Website | nanovibronix.com |
Stock Details
| Ticker Symbol | NAOV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326706 |
| CUSIP Number | 63008J108 |
| ISIN Number | US63008J6038 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Brian M. Murphy | Chief Executive Officer and Director |
| Stephen R. Brown CPA | Chief Financial Officer |
| Dr. Harold Jacob M.D. | Chief Medical Officer and Director |
| Amir Rippel | Vice President of Marketing |
| Lindsey Harrison | Vice President of Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | 8-K | Current Report |
| Apr 9, 2024 | 10-K/A | [Amend] Annual report |
| Apr 9, 2024 | 8-K | Current Report |
| Apr 8, 2024 | 10-K | Annual Report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 28, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 17, 2024 | 8-K | Current Report |
| Dec 11, 2023 | 8-K | Current Report |